Citations

Clear

9383 citation(s) found for "Thomas, PS".

Orchiectomy Markedly Reduces the Concentration of the Three Isoforms of Transforming Growth Factor β in Rat Bone, and Reduction Is Prevented by Testosterone*
Gill, Rajbir K., Turner, Russell T. , Wronski, Thomas J., Bell, Norman H.

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 139 | Issue: 2 | Pages: 546-550

10.1210/endo.139.2.5717 | PMID 9449623 Get It

The Effects of Growth Factors Associated with Osteoblasts on Prostate Carcinoma Proliferation and Chemotaxis: Implications for the Development of Metastatic Disease*
Ritchie, Candace K., Andrews, Laura R., Thomas, Kris G., Tindall, Donald J., Fitzpatrick, Lorraine A.

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 138 | Issue: 3 | Pages: 1145-1150

10.1210/endo.138.3.4974 | PMID 9048621 Get It

Leptin Reduces Ovariectomy-Induced Bone Loss in Rats
Burguera, Bartolomé , Thomas, Thierry , Gori, Francesca , Evans, Glenda L., Riggs, B. Lawrence, Turner, Russell T. , Hofbauer, Lorenz C. , Khosla, Sundeep

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 142 | Issue: 8 | Pages: 3546-3553

10.1210/endo.142.8.8346 | PMID 11459801 Get It

The Expression of Osteoprotegerin and RANK Ligand and the Support of Osteoclast Formation by Stromal-Osteoblast Lineage Cells Is Developmentally Regulated**This work was supported by Grant AG-04875 from the National Institute on Aging.
Gori, Francesca , Dunstan, Colin R. , Spelsberg, Thomas C., Riggs, B. Lawrence, Hofbauer, Lorenz C. , Khosla, Sundeep

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 141 | Issue: 12 | Pages: 4768-4776

10.1210/endo.141.12.7840 | PMID 11108292 Get It

Estrogen Stimulates Gene Expression and Protein Production of Osteoprotegerin in Human Osteoblastic Cells*
Dunstan, Colin R. , Lacey, David L., Spelsberg, Thomas C., Riggs, B. Lawrence, Hofbauer, Lorenz C. , Khosla, Sundeep

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 140 | Issue: 9 | Pages: 4367-4370

10.1210/endo.140.9.7131 | PMID 10465311 Get It

Stimulation of Osteoprotegerin Ligand and Inhibition of Osteoprotegerin Production by Glucocorticoids in Human Osteoblastic Lineage Cells: Potential Paracrine Mechanisms of Glucocorticoid-Induced Osteoporosis1
Gori, Francesca , Riggs, B. Lawrence, Lacey, David L., Spelsberg, Thomas C., Hofbauer, Lorenz C. , Dunstan, Colin R. , Khosla, Sundeep

Mayo Clinic

Endocrinology | January 8, 2014 | Volume: 140 | Issue: 10 | Pages: 4382-4389

10.1210/endo.140.10.7034 | PMID 10499489 Get It

Abstract Osteoporosis is a serious complication of systemic glucocorticoid use. However, while glucocorticoids increase bone resorption in vitro and in vivo, the mechanism(s) of this effect are at present unclear. Recent studies have identified the osteoprotegerin (OPG) ligand (OPG-L) as the final effector of osteoclastogenesis, an action that is opposed by the soluble neutralizing receptor, OPG. Thus, we assessed glucocorticoid regulation of OPG and OPG-L in various human osteoblastic lineage cells using Northern analysis, RT-PCR, and ELISA. Dexamethasone inhibited constitutive OPG messenger RNA (mRNA) steady-state levels by 70–90% in primary (MS) and immortalized stromal cells (hMS), primary trabecular osteoblasts (hOB), immortalized fetal osteoblasts (hFOB), and osteosarcoma cells (MG-63). In hFOB cells, dexamethasone inhibited constitutive OPG mRNA steady-state levels in a dose- and time-dependent fashion by 90%, and also suppressed cytokine-stimulated OPG mRNA steady-state levels. Dexamethasone-induced inhibition of OPG mRNA levels was not affected by the protein synthesis inhibitor, cycloheximide, and was shown to be due to inhibition of OPG gene transcription using a nuclear run-on assay. Moreover, dexamethasone also dose dependently (10−10m–10−7m) inhibited constitutive OPG protein concentrations in the conditioned medium of hFOB cells from 2.59 ± 0.02 ng/ml (control) to 0.30 ± 0.01 ng/ml (88% inhibition; P < 0.001 by ANOVA). Concurrently, dexamethasone stimulated OPG-L mRNA steady-state levels in MS and hFOB cells by 2- and 4-fold, respectively. Treatment of murine marrow cultures with conditioned medium harvested from dexamethasone-treated MG-63 cells increased tartrate-resistant acid phosphatase (TRAP) activity by 54% (P < 0.005) compared with medium harvested from control-treated cells (in the presence of OPG-L and macrophage colony-stimulating factor). Moreover, dexamethasone (10−8m) promoted osteoclast formation in vitro, as assessed by a 2.5-fold increase of TRAP activity in cell lysates (P < 0.001) and the appearance of TRAP-positive multinucleated cells. Our data are thus consistent with the hypothesis that glucocorticoids promote osteoclastogenesis by inhibiting OPG and concurrently stimulating OPG-L production by osteoblastic lineage cells, thereby enhancing bone resorption.
Single-Agent Rituximab for Primary CNS Lymphoma During Pregnancy As a Bridge to Definitive Management
Burnette, Brian L., Jentoft, Mark A., Porrata, Luis F. , Boyce, Thomas G. , Witzig, Thomas E.

Mayo Clinic

Journal of Clinical Oncology | January 7, 2014 | Volume: 32 | Issue: 7 | Pages: e14-e17

10.1200/jco.2012.47.6994 | PMID 24395859 Get It

Triceps insufficiency after the treatment of deep infection following total elbow replacement
Jacobson, Jon A. , Schleck, Cathy D. , Larson, David R., Morrey, B.F. , Duquin, Thomas R. , Sánchez‐Sotelo, Joaquín , Jacobson, Jon A

Mayo Clinic

The Bone & Joint Journal | January 6, 2014 | Volume: 96-B | Issue: 1 | Pages: 82-87

10.1302/0301-620x.96b1.31127 | PMID 24395316 Get It

Treatment of an infected total elbow replacement (TER) is often successful in eradicating or suppressing the infection. However, the extensor mechanism may be compromised by both the infection and the surgery. The goal of this study was to assess triceps function in patients treated for deep infection complicating a TER. Between 1976 and 2007 a total of 217 TERs in 207 patients were treated for infection of a TER at our institution. Superficial infections and those that underwent resection arthroplasty were excluded, leaving 93 TERs. Triceps function was assessed by examination and a questionnaire. Outcome was measured using the Mayo Elbow Performance Score (MEPS).Triceps weakness was identified in 51 TERs (49 patients, 55%). At a mean follow-up of five years (0.8 to 34), the extensor mechanism was intact in 13 patients, with the remaining 38 having bone or soft-tissue loss. The mean MEPS was 70 points (5 to 100), with a mean functional score of 18 (0 to 25) of a possible 25 points.Infection following TER can often be eradicated; however, triceps weakness occurs in more than half of the patients and may represent a major functional problem.Cite this article: Bone Joint J 2014;96-B:82–7.
Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres
Robinson, Don, Reynolds, Matthew W. , Dispenzieri, Angela , Vermeulen, Jessica, Payne, Krista, Schramm, J, Ristow, Kay M., Desrosiers, Marie-Pierre, Yeomans, Karen, Teltsch, Dana Y., Swain, Richard S. , Rotella, Philip, Velde, Helgi van de , Casper, Corey , Vermeulen, Jessica, Habermann, Thomas M. , Dispenzieri, Angela

Mayo Clinic

British Journal of Haematology | January 6, 2014 | Volume: 165 | Issue: 1 | Pages: 39-48

10.1111/bjh.12717 | PMID 24387011 Get It

Elevated serum monoclonal and polyclonal free light chains and interferon inducible protein‐10 predicts inferior prognosis in untreated diffuse large B‐cell lymphoma
Maurer, Matthew J. , Stenson, Mary, Allmer, Cristine, Macon, William R. , Link, Brian K. , Katzmann, Jerry A., Witzig, Thomas E. , Gupta, Mamta , Maurer, Matthew , Link, Brian K

Mayo Clinic

American Journal of Hematology | January 2, 2014 | Volume: 89 | Issue: 4 | Pages: 417-422

10.1002/ajh.23658 | PMID 24382707 Get It

The detection of serum free light (FLC) is useful in the diagnosis of several hematological diseases. The role and biological relevance of monoclonal or polyclonal FLC elevations in predicting long‐term outcome in diffuse large B‐cell lymphoma (DLBCL) is unknown. We determined the relationship of the type of FLC elevations to outcome, tumor genotype, and pattern of serum cytokine elevations in 276 patients with untreated DLBCL. Elevated FLC was an adverse prognostic factor through 6 years of follow‐up (monoclonal, Event free survival (EFS) HR = 3.56, 95% CI: 1.88–6.76, P <0.0001; polyclonal, EFS HR = 2.56, 95% CI: 1.50–4.38, P = 0.0006). About 73% of DLBCL tumors with monoclonal FLC elevations were activated B‐cell type (ABC) versus 33% from patients with normal FLC. Only ABC‐DLBCL lines secreted kappa FLC in vitro and this secretion could be inhibited by the NF‐κB inhibitor bortezomib. Patients with monoclonal FLC had significantly (all P <0.001) increased serum levels of IL‐12, sIL‐2Rα, IL‐1R, and IP‐10. Patients with polyclonal elevations of FLC had higher levels of IL‐6 (P = 0.033), IL‐8 (P =0.025), sIL2Rα (P = 0.011), and IL‐1R1 (P = 0.041). The combination of elevated FLC and a CXC superfamily chemokine IP‐10 predicted a particularly inferior outcome characterized by late relapse. These increased abnormal FLC and cytokines are potentially useful biomarkers for prognosis and selecting agents for untreated DLBCL. Am. J. Hematol. 89:417–422, 2014. © 2014 Wiley Periodicals, Inc.